Could Bristol-Myers Squibb (BMY) Outperform Novartis (NVS) as CAR-T Safety Concerns Shake the Sector?
Covered in this story
What has happened since
- Bristol Myers Squibb is down 4.2% since this was published, 40 days ago.
- Novartis is up 12.8% since this was published, 40 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Bristol Myers Squibb
- Wells Fargo: $57.6 → $60 by Oct 2027 · Equal Weight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $BMY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Bristol Myers Squibb →Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.